-
Strongbridge Bio's Recorlev US Application For Cushing's Syndrome Under Review, Potential Approval In Early 2022
Thursday, May 13, 2021 - 9:28am | 185Read More...The FDA has accepted to review Strongbridge Biopharma plc's (NASDAQ: SBBP) marketing application for Recorlev (levoketoconazole) to treat endogenous Cushing's syndrome. Earlier than anticipated, the Company received the official Day 74 letter from the FDA. Within the...
-
Strongbridge's Recorlev Shows Improvements in Cortisol Control In Cushing's Syndrome, Diabetes
Thursday, April 8, 2021 - 6:52am | 301Read More...Results from a sub-analysis of patients with diabetes mellitus from Phase 3 SONICS study evaluating Strongbridge Biopharma plc's (NASDAQ: SBBP) Recorlev (levoketoconazole) for endogenous Cushing's syndrome were published in Frontiers in Endocrinology....
-
Strongbridge Biopharma Stock Trading Higher On Detailed Recorlev Data In Cushing's Syndrome
Monday, March 22, 2021 - 8:04am | 311Read More...Strongbridge Biopharma plc (NASDAQ: SBBP) has announced detailed results from the previously reported Phase 3 LOGICS study of Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome. Data were presented at the Annual Meeting of the Endocrine Society. The...
-
Strongbridge Biopharma Shares Are Trading Higher On Filing Recorlev US Application For Endocrine Disease
Tuesday, March 2, 2021 - 9:57am | 157Read More...Strongbridge Biopharma plc (NASDAQ: SBBP) has submitted a marketing application seeking approval for Recorlev (levoketoconazole) for the treatment of endogenous Cushing's syndrome, to the FDA. Endogenous Cushing's syndrome is a rare endocrine disease caused by chronic...
